多西他赛联合表柔比星方案化疗对三阴性乳腺癌患者p53及血管内皮生长因子的影响

Abstract
Figure/Table
References (22)
Related Citation (15)

Download: PDF (0 KB) HTML (42 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the effect of Docetaxel combined with Epirubicin regimen chemotherapy in the treatment of triple negative breast cancer (TNBC) and influence on tumor suppressor protein p53 (p53) and vascular endothelial growth factor (VEGF).Methods A total of 124 female TNBC patients admitted to our hospital from January 2013 to December 2015 were selected as the research subjects, and they were divided into experimental group (n=62)and control group (n=62) according to the random number table method.The Control group received Cyclophosphamide combined with Epirubicin regimen chemotherapy, while the experimental group received Docetaxel combined with Epirubicin regimen chemotherapy.The levels of serum VEGF subtypes such as VEGF A, VEGF B, VEGF C and p53 positive expression rates were observed before and after treatment in the two groups.The clinical efficacy, 1 to 3-year survival rates and incidence of toxic and side effect in the two groups of patients were compared.Results After treatment, the levels of VEGF A, VEGF B, and VEGF C in the experimental group were lower than those in the control group, and the differences were statistically significant (P＜0.05).After treatment, the positive expression rate of p53 in the experimental group was lower than that in the control group, and the objective response (OR) rate was higher than that in the control group, the differences were statistically significant (P＜0.05).There were no significant differences in the 1-and 2-year survival rates between the two groups of patients (P＞0.05).The 3-year survival rate in the experimental group was higher than that in the control group, and the difference was statistically significant (P＜0.05).There was no significant difference in the incidence of toxic and side effect between the two groups of patients (P＞0.05).Conclusion Neoadjuvant chemotherapy with Docetaxel and Epirubicin can effectively kill TNBC, and inhibit the expression of VEGF subtypes and p53.The 3-year survival rate is high, the toxic and side effect is less, and it is safe and reliable.

Key words： Docetaxel Epirubicin Neoadjuvant chemotherapy Triple negative breast cancer Tumor suppressor protein p53 Vascular endothelial growth factor

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CUI Hai
	JIN Yong-min
	GAO Ai-hua

Cite this article:

CUI Hai,JIN Yong-min,GAO Ai-hua. Influence of Docetaxel combined with Epirubicin regimen chemotherapy on p53 and vascular endothelial growth factor in patients with triple negative breast cancer[J]. 中国当代医药, 2020, 27(8): 8-11转15.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I8/8

[1]	Zhao Z，Li L，Du P，et al.Transcriptional downregulation of miR-4306 serves as a new therapeutic target for triple negative breast cancer[J].Theranostics，2019，9（5）：1401-1416.
[2]	Uscanga-Perales GI，Santuario-Facio SK，Sanchez-Dominguez CN，et al.Genetic alterations of triple negative breast cancer（TNBC）in women from Northeastern Mexico[J].Oncol Lett，2019，17（3）：3581-3588.
[3]	刘超，刘宇宏，樊华，等.三阴性乳腺癌细胞免疫状态和Th1/Th2 细胞因子的变化[J].现代肿瘤医学，2016，24（2）：234-236.
[4]	Shimizu T，Saijo N.Common toxicity criteria：version 2.0，an improved reference for grading the adverse reaction of cancer treatment[J].Nihon Rinsho，2003，61（6）：937-942.
[5]	杨学宁.实体瘤治疗疗效评价标准——RECIST[J].循证医学，2004，4（2）：85-90，111.
[6]	吴龙，刘晨，蒋宏传，等.乳腺癌术后并发卵巢癌的microRNA 标志物筛选及临床早期预测研究[J].中国医药导报，2019，16（7）：15-19.
[7]	Lee CK，Scott C，Lindeman GJ，et al.Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer，recurrent BRCA ovarian cancer，non-BRCA triple-negative breast cancer，and non-BRCA ovarian cancer[J].Br J Cancer，2019，120（3）：279-285.
[8]	Bas E，Naziroglu M.Selenium attenuates docetaxel-induced apoptosis and mitochondrial oxidative stress in kidney cells[J].Anticancer Drugs，2019，30（4）：339-346.
[9]	Li B，Chen L，Luo HL，et al.Docetaxel，cisplatin，and 5-fluorouracil compared with epirubicin，cisplatin，and 5-fluorouracil regimen for advanced gastric cancer：A systematic review and meta-analysis[J].World J Clin Cases，2019，7（5）：600-615.
[10]	Sugiyama K，Iwakoshi A，Satoh M，et al.Primary mediastinal HER2-positive apocrine carcinoma in mature teratoma treated with anti-HER2 therapy and chemoradiation[J].In Vivo，2019，33（2）：551-557.
[11]	董久兴，赵佳，刘琪，等.动脉灌注多西他赛和表柔比星治疗乳腺癌术后胸壁复发的远期效果分析现代肿瘤医学，2017，25（21）：3435-3438.
[14]	Jiang D，Rusling JF.Oxidation chemistry of DNA and p53 tumor suppressor gene[J].ChemistryOpen，2019，8（3）：252-265.
[16]	聂明辉，戚林，李志生，等.外源性p53 基因导入对乳腺癌细胞系MCF-7 中MDM2 表达的影响[J].现代肿瘤医学，2015，23（8）：1048-1050.
[12]	Kojima Y，Kawamoto H，Nishikawa T，et al.Feasibility study of weekly Nanoparticle Albumin-Bound Paclitaxel（150 mg/m2）followed by Fluorouracil，Epirubicin，and Cyclophosphamide therapy as neoadjuvant chemotherapy for HER2-negative breast cancer[J].Clin Breast Cancer，2018，18（5）：374-379.
[13]	Joensuu H，Kellokumpu-Lehtinen PL，Huovinen R，et al.Adjuvant Capecitabine in combination with Docetaxel，Epirubicin，and Cyclophosphamide for early breast cancer：the randomized clinical FinXX trial[J].JAMA Oncol，2017，3（6）：793-800.
[15]	Zhang X，Qi Z，Yin H，et al.Interaction between p53 and Ras signaling controls cisplatin resistance via HDAC4-and HIF-1α-mediated regulation of apoptosis and autophagy[J].Theranostics，2019，9（4）：1096-1114.
[17]	Yu X，Carpizo DR.Flipping the "switch" on mutant p53 by zinc metallochaperones：how a brief pulse of zinc can reactivate mutant p53 to kill cancer[J].Oncotarget，2019，10（9）：918-919.
[18]	Barr JA，Hayes KE，Brownmiller T，et al.Long non-coding RNA FAM83H-AS1 is regulated by human papillomavirus 16 E6 independently of p53 in cervical cancer cells[J].Sci Rep，2019，9（1）：3662.
[19]	Apte RS，Chen DS，Ferrara N.VEGF in signaling and disease：beyond discovery and development[J].Cell，2019，176（6）：1248-1264.
[20]	Sadremomtaz A，Mansouri K，Alemzadeh G，et al.Dual blockade of VEGFR1 and VEGFR2 by a novel peptide abrogates VEGF-driven angiogenesis，tumor growth，and metastasis through PI3K/AKT and MAPK/ERK1/2 pathway[J].Biochim Biophys Acta Gen Subj，2018，1862（12）：2688-2700.
[21]	Samadi P，Saki S，Dermani FK，et al.Emerging ways to treat breast cancer：will promises be met?[J].Cell Oncol（Dordr），2018，41（6）：605-621.
[22]	Huang YW，Tsai HC，Wang SW，et al.Amphiregulin promotes vascular endothelial growth factor-C expression and lymphangiogenesis through STAT3 activation in human chondrosarcoma cells[J].Cell Physiol Biochem，2019，52（1）：1-15.